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SUMMARY. Preeclampsia is one of the most serious complications of pregnancy. Although the etiology of preeclampsia 
remains obscure, examinations of central hemodynamics and recent epidemiologic data have challenged its homogenous 
origin. Hypertension could theoretically be secondary to elevated resistance or elevated cardiac output. Accumulating 
data suggest that both, organ hypoperfusion due to increased resistance of vasculature, the vascular content and also 
hyperperfusion due to augmented fluid retention may lead to hypertension with proteinuria in pregnancy. »Functio 
 laesa« secondary to hypoperfusion of kidneys manifests in proteinuria in hypoperfusion type but the hypertension itself 
may also lead to moderate but significant proteinuria during pregnancy. Examination of central hemodynamics seems to 
be a useful tool for early differentiation of hypo- and hyper-perfusion types for evaluating the outcome, appropriate 
management and also accurate patients’ recruitment for studies.
Pregled
Klju~ne rije~i: hipertenzija trudno}e, podvrste preeklampsije, postupak
SA`ETAK. Preeklampsija je jedna od najozbiljnijih komplikacija trudno}e. Premda etiologija preeklampsije ostaje nepo-
znata, istra`ivanja centralne hemodinamike i svje`i epidemiolo{ki podaci su doveli u pitanje jedinstvenost njezina po-
stanka. Hipertenzija teoretski mo`e nastati sekundarno zbog povi{enog otpora ili zbog pove}anog sr~anog minutnog 
volumena. Podatci upu}uju da oboje, hipoperfuzija organa zbog pove}anog krvo`ilnog otpora i volumena te isto tako 
hiperperfuzija zbog pove}anog zadr`avanja teku}ine, mogu u trudno}i uzrokovati hipertenziju s proteinurijom. »Functio 
laesa« zbog hipoperfuzije bubrega o~ituje se kao proteinurija u hipoperfuzijskom tipu, a i sama hipertenzija mo`e 
proizvesti umjerenu do zna~ajnu proteinuriju trudno}e. Istra`ivanje centralne hemodinamike ~ini se da je koristan na~in 
za rano razlikovanje hipo- i hiper-perfuzijskog tipa da bi se prosudio ishod, odgovaraju}e lije~enje te pacijentice priklad-
ne u izboru istra`ivanja.
Introduction
Elevated blood pressure, chronic or pregnancy-in-
duced, complicates 6−30% of all pregnancies. The most 
important hypertensive gestational condition is the pre-
eclampsia-eclampsia syndrome. Although the etiology 
of PE remains obscure, studies with central hemody-
namics and also epidemiologic data have challenged its 
homogenous pathogenesis. Different pathways leading 
to hypertension with proteinuria during the second half 
of pregnancy not only may disturb the results of scien-
tific studies but may alter our management strategies as 
well.
The goal of this review is to support the theory of dif-
ferent origination of classic symptoms of PE.
Chronic hypertension in pregnancy
Chronic hypertension is obvious if hypertension was 
known before conception and can be presumed if in-
creased blood pressure is detected prior to the 20th week 
of gestation. Similarly, existance of elevated blood pres-
sure over 12 weeks postpartum refers to chronic mani-
festation. Most patients in such cases have essential hy-
pertension but some have underlying renal, endocrine, 
or vascular disease. Perinatal mortality in pregnancies 
with chronic uncomplicated hypertension is similar to 
that in normotensive pregnancies; however, the inci-
dence of intrauterine growth restriction (IUGR) is high-
er. Therefore, medical supervision throughout whole 
gestation is essential. The use of antihypertensives in 
uncomplicated cases is a controversial issue. It is widely 
accepted that control of uncomplicated mild essential 
hypertension has little, if any, long-term benefit.1 One 
of the main controversies concerns the effect of reduc-
tion of blood pressure on placental blood flow. In addi-
tion, control of blood pressure seems to fail to prevent 
the subsequent development of superimposed pre-
eclampsia, which develops in about 20 percent of chron-
ically hypertensive pregnant women. However, diastolic 
blood pressure above 100 mm Hg requires hospitaliza-
tion and antihypertensive therapy should be considered. 
In general, if the medication used prior to pregnancy is 
considered safe it should be continued; if not, α-meth-
yldopa could be the first choice. Serial examination of 
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also fetal well-being are the usual examinations during 
prenatal care in such cases, regardless of known under-
lying disease.
Pregnancy-induced hypertension
The term of pregnancy-induced hypertension includes 
cases of gestational hypertension (GH, solely hyper-
tension), preeclampsia: (PE, gestational hypertension 
with significant proteinuria), and eclampsia. The clini-
cal symptoms appear during the second half of preg-
nancy, seldom in childbed period.
Although the outcome of GH with appropriate prena-
tal care is not worse than it is in normotensive pregnan-
cies and blood pressure control is rarely required, it 
mandates close attention since nearly half of these cases 
develops PE. PE complicates 2% to 7% of all pregnan-
cies. In many countries PE is one of the leading causes 
of maternal mortality and leads to about a five-fold in-
crease in perinatal mortality.
Nowadays preeclamptic cases are distinguished as 
early- or late-onset types. This separation is not well-
defined. In general, serious condition and outcome is 
characteristic in early-onset but not in late-onset cases. 
Denominations of early- or late-onset suggest that these 
subgroups are distinct only in gestational age when PE 
symptoms appear. However, epidemiologic studies have 
recently revealed that incidence of both, small-for-ges-
tational-age (SGA) and large-for-gestational-age (LGA) 
newborns were elevated in cases when PE had been 
 diagnosed.2–4 Statistical confirmation of this old clinical 
notice markedly supports the theory of distinct origi-
nation of gestational hypertensive conditions because 
large fetus is obviously more than the absence of 
IUGR.
Different pathogenesis of PE is an attractive hypoth-
esis. This is not only in accordance with wide clinical 
experiences, but could also explain the controversies of 
results of different former studies in PE, especially in 
central hemodynamics. Increased systemic vascular re-
sistance (SVR) with contracted blood volume is a clas-
sical hallmark of PE.5–7 End-organ dysfunction, placen-
tal insufficiency with oligohydramnios, IUGR (result-
ing SGA newborn), and fetal hypoxemia represent the 
characteristic outcome of this hypoperfusion condition.8 
On the contrary, other examiners found high cardiac 
output (CO) with low SVR in pre-eclamptic patients 
and determined PE as a hyperdynamic state.9,10 The cor-
relation between maternal CO and fetal birth weight in 
PE is well documented,11, 12 so infants in such hyperper-
fusion cases reasonably tend to be LGA. Similar contro-
versy has been found in brain blood flow, as both hypo-
perfusion and hyperperfusion may occur in PE.13
Occurrence of low CO with SGA newborn and also 
high CO with LGA newborns suggest a different patho-
genesis of hypoperfusion and hyperperfusion/hyperdy-
namic models; however, both of them are fit for the tra-
ditional criteria for PE.
Hypoperfusion model of preeclampsia
Accumulating data suggest that the failure of mater-
nal immune tolerance may account for hypoperfusion 
PE.14 This type can be considered as a two-stage dis-
ease. Abnormal placentation (first stage) through endo-
thelial damage is responsible for the potential of end-
organ manifestations (second stage). The first stage is 
characterized by effects of anti-angiogenic substances 
such as the soluble endoglin (sEng),15 fms-like tyrosine 
kinas-1 (sFlt-1),16 and human interferon-inducible pro-
tein 10 (IP-10 or CXC10)17 which bind and neutralize 
different growth factors [vascular endothelial growth 
factor (VEGF), placental growth factor(PlGF), and 
transforming growth factor-β (TGF-β)] required for 
placental and fetal angiogenesis. Agents directly from 
this shallowly implanted placenta and also from acti-
vated leukocytes or platelets may represent the link be-
tween abnormal placentation and endothelial inflamma-
tory injury. Recent candidates are the anti-angiogenic 
agents; free oxygen radicals and some cytokines, first of 
all tumor necrosis factor-α;18, 19, 20 thrombogenic content 
of microparticles released from the surface of different 
cells;21 syncytiotrophoblast microvilli;22 fetal cells and 
cell-free fetal DNA23 circulating in a relatively huge 
amount in preeclamptic maternal bloodstream. Conse-
quently, markers of endothelial injury e. g. fibronectin,24 
soluble thrombomodulin,25 or von Willebrand factor 26 
show elevated levels in PE.
Changes of vascular function, hemodynamics, he-
morheology, and hemostasis with platelet activation, 
secondary basically to endothelial dysfunction and be-
ing in a close relation to each other, lead to end-organ 
dysfunctions in hypoperfusion PE (Fig. 1).
Figure 1. Development of hypertension (H), proteinuria (P), and small for 
gestational age (SGA) newborn in hypoperfusion model of preeclamp-
sia.
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Vascular alterations
In the first and second trimester of normal pregnancy 
throphoblast cells invade the supporting spiral arteries. 
Incorporating to the vessel wall, throphoblast cells de-
stroy the endothelial and muscular layers. These vessels 
become wider in diameter and unable to contract. In hy-
poperfusion PE this remodeling is inadequate: approxi-
mately one third to one half of spiral arteries escape 
from endovascular throphoblast invasion and adrener-
gic nerve supply of muscular layer also remains intact.27 
Inappropriate remodeling, which can also be seen in in-
trauterine growth retardation syndrome, could be the 
consequence of initial maternal rejection of thropho-
blast.
Beyond this special abnormality of placental vessels, 
patients with hypoperfusion PE suffer from general en-
dothelial injury. Endothelial cells exhibit adjacent foam 
cell invasion and many vessels (e.g. placenta, glomeru-
li) are occluded by fibrinoid material.28 Damaged en-
dothelial cells produce less vasodepressive substances, 
e.g. nitric oxide (NO), prostacyclin (PGI
2
), endotheli-
um-derived hyperpolarizing factor (EGHF) than nor-
mal endothelium, but excrete vasoconstrictors, e.g. en-
tothelin-1 (ET-1) contributing to hypertension. In addi-
tion, vascular smooth muscle cells exhibit increased 
sensitivity to all vasopressors.
Hemodynamics
Generalized smooth muscle relaxation due to high 
endothelial production of vasodepressors is a character-
istic feature of normal pregnancy. Increasing capacity 
of the vasculature triggers plasma volume augmenta-
tion;29 CO increases and hematocrit falls subsequently. 
In hypoperfusion PE, the insufficient excretion of relax-
ing agents and also a high production of vasoconstric-
tors plasma volume and CO may even decrease while 
SVR and blood pressure increase. Placental/fetal blood 
supply, and subsequently fetal somatic development 
seem to be related to circulating blood volume too; 
 neonatal birth weight shows a positive correlation to 
maternal CO in both normal and hypertensive pregnan-
cies.11,12,30
Hemorheology
Blood perfusion of an organ can be expressed by the 
(simplified form) of Poisseuille-Hagen equation: Perfu-
sion or CO = Pressure(difference) / Resistance. Resis-
tance is determined by vascular diameters, and rheo-
logical properties of the blood.
In large vessels, blood viscosity depends basically on 
hematocrit. Because of the insufficient hemodilution in 
PE, hematocrit is relatively high. Blood and plasma hy-
perviscosity are early findings and contribute to reduced 
tissue (e.g. intervillous) blood flow; plasma viscosity 
correlates inversely with neonatal birth weight.31
Deformability of erythrocytes allows the cells to pass 
capillaries having smaller diameters than erythrocytes 
(3–4 µm vs. 7–8 µm). Furthermore, this phenomenon 
decreases whole blood viscosity because erythrocytes 
elongate in flow due to shear stress. Erythrocyte de-
formability has been found to be decreased in PE which 
may contribute to the decreased capillary circulation.32,33 
In slowing flow erythrocytes tend to aggregate and also 
to break in blocked capillaries (microthrombosis and 
mechanical peripheral hemolysis).
In collapsing microcirculation hypertension could be 
beneficial for maintaining organ (e.g. placental) perfu-
sion.34
Hypercoagulation and platelet activation
It is well known for some decades that platelets and 
also intravascular coagulation cascade are activated in 
PE. Damaged endothelial cells produce more adhesive 
substances (e.g. fibronectin, vascular cell adhesion mol-
ecule-1, E-selectin) and possess less antithrombotic ca-
pacity (e.g. weak thrombomodulin effects) than normal 
endothelial cells.24, 25, 35 Activated platelets not only re-





also increase the expression of adhesive agents.36 Plate-
lets this way enhance the endothelium−leukocyte con-
tact and trigger leukocyte arrest and transendothelial 
migration.37 Damaged erythrocytes show an enhanced 
aggregability as well.33 In the most severe cases gener-
alized microthrombosis develops finally. Therefore, al-
tered hemostasis may contribute to the collapse of mi-
crocirculation and subsequent multiorgan hypoperfu-
sion and dysfunction.
In this compound process platelets play a pivotal role. 
Platelets are activated in different actions and condi-
tions such as immune answer, blood coagulation, or de-
fense against infection. The most potent platelet-acti-
vating agents are collagen, ADP, TXA
2
, and thrombin. 
Appearance of fetal cells (or debris) in maternal circula-
tion initiates immune responses in which platelets are 
important signaling cells and also influence leukocyte 
functions.37,38 Further platelet activation is caused by the 
impairment of endothelium as it exposes the subendo-
thelial collagen to vessel content. ADP escapes from 
damaged erythrocytes and TXA
2
 is released from acti-
vated platelets. Thrombin concentration is also increased 
in PE.
The relationship between PE and infection was posed 
by the PE model based on low-dose endotoxin infusion 
in pregnant rats.39 Since then several studies found cor-
relation between PE and different forms of infection.40 
The link between PE and different inflammations may 
be the further enhance of platelet activation, since plate-
lets are involved in anti-infection reactions too by pro-
ducing bactericide agents (thrombocidin I and II), and 
also by the internalization of bacteria and viruses.37
Hyperperfusion model of pre-eclampsia
Pathophysiology of hyperperfusion model of PE was 
outlined first on the basic findings of high CO and low 
SVR in preeclamptic patients.9,10 According to Pois-
seuille-Hagen equation hypertension can be a result of 
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not only elevated vascular resistance but also high CO. 
It has been proposed that hyperdynamic condition is as-
sociated with extreme vasodilatation, elevated CO, and 
increased capillary leak. The leakage accounts for the 
characteristic visible and pulmonary or cerebral edema. 
Vasodilatation of the glomerular afferent arteriole, 
which exposes capillaries to increased flow and system-
ic pressure, could mediate the development of hyperten-
sion and proteinuria. This theory is supported by renal 
artery blood flow velocimetry examinations. Renal au-
toregulation is altered in PE, leaving glomeruli unpro-
tected from increased blood pressure.41 In accordance, 
the hypertension and the proteinuria correlate with a se-
verity of glomerular lesion. In general, relaxed terminal 
arterioles and capillary beds could be damaged by hy-
pertensive overflow exposure: mesangial and subendo-
thelial deposits with focal segmental hyalinosis and 
sclerosis are usual findings in hypertension.42 These al-
terations might also be related to hyperperfusion lesion 
in pregnancy (Fig. 2).
tional weight gain.46 Obesity is known to be associated 
with gestational hypertension or preeclampsia;47 gesta-
tional edema is associated with higher fetal weight.48 
Proteinuria is seldom serious and may even improve 
with blood pressure control. Hematocrit level and blood 
viscosity increase with gaining extravasal fluid accumu-
lation.
Management principles in different types
of preeclampsia
Management strategies will obviously differ for hy-
po- or hyperperfusion PE, therefore, an early differen-
tiation is mandatory. Examination of maternal central 
hemodynamics seems to be a useful tool because high 
stroke volume (SV) or CO excludes hypoperfusion back-
ground; in general, a CO of 8 l/min or more excludes 
hypoperfusion model.46 For hemodynamic examination 
echocardiography and bioimpedance cardiography are 
non-invasive methods; the invasive examination by 
thermodilution with Swan-Ganz catheter is justified 
rather in serious but stable cases when immature fetal 
lung requires pregnancy prolongation.
It seems that poor outcome is more common in hypo-
perfusion type PE. Delivery is indicated after 34 weeks’ 
gestation in severe PE and also earlier if serious compli-
cation (e.g. imminent eclampsia, severe fetal growth 
restriction, non-reassuring fetal tests, or HELLP syn-
drome) develops. Hypoperfusion PE can be predicted in 
the midtrimester by determination of the ratio of PlGF / 
sEng or sFLt-1/ PlGF ratios.49,50
For the expectant management in moderate hypoper-
fusion PE, deliberate intravenous volume expansion 
with vasodilators (e.g. hydralazine, nifedipine) may be 
beneficial.51 However, antihypertensives fail to improve 
the outcome.52 Calcium dobesilate augments basal and 
reactive NO production of the endothelium, improves 
blood rheology, and decreases the blood pressure this 
way.53 Antihypertensive treatment (α-methyldopa, ni-
fedipin, labetalol) is indicated in severe PE when sys-
tolic blood pressure is at least 160 mmHg or diastolic 
value is at least 110 mmHg. Use of magnesium sulfate 
is associated with eclampsia preventing effect too in 
contrast to any other anticonvulsive or antihypertensive 
agent.54 Corticosteroid administration for accelerating 
fetal lung maturation should always be considered be-
fore 34 weeks’ gestation.55
Patients with hyperperfusion PE require rather hyper-
tension control with an agent that has no vasodilator 
activity (e.g. cardio-selective β-blockers).9 In the ab-
sence of hemoconcentration, use of diuretics seems to 
be justified. Serious complication is rare;45 however 
 placental abruption is frequently associated with pre-
eclamptic edema.
Eclampsia. Cerebral perfusion.
Eclampsia appears approximately in 5 percent of pre-
eclamptic pregnancies. Maternal and perinatal mortality 
Figure 2. Possible development of hypertension (H), proteinuria (P), and 
large for gestational age (LGA) newborn in hyperperfusion model of pre-
eclampsia.
Slika 2. Mogu}i razvoj hipertenzije (H), proteinurije (P) i velikog djeteta 
u hiperperfuzijskom modelu preeklampsije.
PH
parenchyma hyperperfusionincreased blood volume
excessive Na-retention?
LGA fetus
In this hyperperfusion model of PE placental blood 
perfusion is increased and newborns’ weights tend to be 
LGA. In accordance, it has been demonstrated that birth 
weight progressively increases with increasing blood 
pressure until the hypertensive range is reached; this ef-
fect is probably mediated by increased uteroplacental 
blood perfusion.43
Vasodilatation is considered as the trigger for blood 
volume augmentation in pregnancy.29 The disturbance 
of this mechanism, e.g. a higher production of vasode-
pressor substances or increased sodium retention44 
might explain the overflow of the vasculature and sub-
sequent hypertension, edema, and endothelial lesion in 
hyperperfusion PE. It is not elucidated whether in-
creased transparency is the only symptom of endothe-
lial dysfunction in hyperperfusion PE. However, fibro-
nectin levels of maternal serum, a marker of endothelial 
injury, exhibit a negative correlation to neonatal birth 
weights.45
Patients in this group are characteristically obese, 
necessarily edematous, and possess an increased gesta-
259
Gynaecol Perinatol 2010;19(4):255–260 Tamás P. et al. Hypertensive Disorders of Pregnancy
ranges from 0.5% to 14% and from 10% to 28%, re-
spectively. Eclampsia is considered as brain dysfunc-
tion secondary to hypoxia which is the part of general-
ized organ dysfunction in serious PE. Examination of 
cerebral blood flow in pre-eclamptic women may give 
information about events during eclampsia.
Results of blood velocity examinations in middle ce-
rebral (also retinal and ophthalmic) arteries by transcra-
nial Doppler ultrasonography in preeclamptic patients 
are also controversial. Cerebral vasoconstriction with 
increased perfusion pressure is a common finding.55,56 
In this hypoperfusion condition the brain underperfu-
sion may account for eclampsia. Microthrombosis was 
already found in women died due to eclampsia more 
than a century ago.57 In addition, postmortem examina-
tions suggest also the involvement of coagulation and 
rheological factors in the development of eclampsia.
Alternatively, a significant number of women with 
severe PE have cerebral overperfusion. In this group the 
uncontrolled perfusion pressure may cause vascular da-
mage leading to hypertensive encephalopathy and over-
perfusion injury.13, 58
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